Abbott's new glucose monitoring device could be used by millions of diabetes patients in the US after government-funded health schemes agreed to pay for it.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.